Sponsors (2)
The bill increases predictability, transparency, and modest centralized support for pediatric research and rare‑disease flexibility, but it also reduces some FDA enforcement leverage and creates administrative shifts that risk slower or reduced pediatric evidence generation and greater uncertainty for clinicians, families, and providers.
Drug sponsors and applicants (including small companies and contract holders) gain clearer, more predictable enforcement rules: required notice and a 45‑day response window, a 180‑day non‑retroactivity transition, limits on enforcement for sponsors who showed due diligence, and protection for products no longer marketed — reducing surprise penalties and increasing regulatory predictability.
Patients — especially children — and the public benefit from greater FDA transparency and accountability because the agency must track and publicly report pediatric study deferral completions and the details/amounts of penalties or settlements, increasing visibility into pediatric safety timelines and enforcement outcomes.
Rare‑disease patients and sponsors gain more flexible and predictable pathways: clarified waiver/deferral procedures, an automatic‑waiver list, and acceptance of real‑world evidence can reduce trial burdens and speed access to therapies when pediatric benefit is unlikely.
Children and patients (including those with chronic or rare conditions) face a heightened risk of delayed, reduced, or missing pediatric safety and dosing data because limiting and delaying section 303 enforcement, excluding products no longer marketed, and easing rare‑disease study requirements weaken FDA's leverage and lower incentives to complete pediatric studies.
Federal agencies, NIH institutes, and drug sponsors will bear additional administrative burden and process complexity (compiling/publicing enforcement data, creating/maintaining waiver lists and guidance, and managing small NIH transfers), which could divert staff time and complicate budgeting and planning.
Hospitals, clinicians, and families may shoulder greater costs and clinical uncertainty because reduced pediatric trial incentives and fewer required studies (particularly for rare diseases) can leave providers to make off‑label dosing decisions without robust pediatric evidence.
Based on analysis of 5 sections of legislative text.
Adds procedural protections and reporting for pediatric-study enforcement, allows small NIH fund transfers to pediatric programs, and narrows pediatric requirements for orphan drugs while requiring FDA guidance.
Introduced February 25, 2025 by John F. Reed · Last progress February 25, 2025
Changes the rules for pediatric drug study requirements by adding procedural protections for companies, narrowing when civil enforcement can be used, and barring enforcement for products no longer on the market; requires the FDA to report on compliance and publicly list penalties or settlements for pediatric-study violations; allows the NIH director to shift up to 1% of each institute’s pediatric research funds into a central pediatric studies program for fiscal years 2026–2030; and largely exempts drugs with an orphan designation from routine pediatric-assessment obligations unless the Secretary of HHS finds a meaningful pediatric benefit and issues implementing guidance. Overall, the legislation increases formal procedures and transparency around pediatric-study enforcement, creates a temporary NIH funding transfer authority to support pediatric studies, and directs the FDA to issue guidance and hold a public meeting on how pediatric requirements apply to orphan-designated products — with specified timelines for drafting and finalizing that guidance.